LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

Home・Stock List・KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc

Open

SectorHealthcare

26.78

Buy Sell

Overview

Share price change

24h

Current

Min

26.76

Max

26.82

Key metrics
By Trading Economics
Income	-5.4M
Sales	61M 60M
EPS	-0.43
Profit margin	-8.965
Employees	275
EBITDA	50M -11M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+8.97% upside

Dividends
By Dow Jones
Next Earnings	21 May 2026

Market Stats
By TradingEconomics
Market Cap	5.4M 1.4B
Previous open	26.78
Previous close	26.78

News Sentiment

By Acuity

57%

43%

296 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

12.19 / 12.825 Support & Resistance

KalVista Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Sept 2025, 17:27 UTC

Major Market Movers

KalVista Pharmaceuticals Shares Drop After Notes Offering Prices

7 Jul 2025, 11:30 UTC

Major Market Movers

KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug

31 Mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 Mar 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

Peer Comparison

Price change

KalVista Pharmaceuticals Inc Forecast

Price Target

By TipRanks

8.97% upside

12 Months Forecast

Average 29.17 USD 8.97%

High 35 USD

Low 27 USD

Based on 8 Wall Street analysts offering 12 month price targets forKalVista Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to KalVista Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

12.19 / 12.825Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

296 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.